Patents by Inventor Nigel Waters

Nigel Waters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF TREATING CANCERS WITH ALKYNE SUBSTITUTED QUINAZOLINE DERIVATIVES
    Publication number: 20240075042
    Abstract: The present disclosure relates to methods of treating or preventing cancer (e.g., advanced solid cancer) using Compound No. 1 or Compound No. 2: or a pharmaceutically acceptable salt thereof. The present disclosure also relates to pharmaceutical compositions and pharmaceutical kits suitable for the treatment or prevention.
    Type: Application
    Filed: November 2, 2021
    Publication date: March 7, 2024
    Inventors: Elizabeth BUCK, Matthew O'CONNOR, Darlene ROMASHKO, Tai-An LIN, Alexander FLOHR, Luca ARISTA, Iwona WRONA, Matthew LUCAS, Chris ROBERTS, Giorgio OTTAVIANI, Sherri SMITH, Nigel WATERS
  • PEDIATRIC DOSING FOR TREATMENT OF CANCER WITH AN EZH2 INHIBITOR
    Publication number: 20210008075
    Abstract: The disclosure provides a method of treating a an INI1-deficient tumor in a subject in need thereof comprising administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In a preferred embodiment of this method, the subject is pediatric and the EZH2 inhibitor is Tazemetostat.
    Type: Application
    Filed: May 6, 2020
    Publication date: January 14, 2021
    Inventors: Heike KEILHACK, Sarah K. KNUTSON, Nigel WATERS
  • TREATMENT OF LEUKEMIA VIA THE ADMINISTRATION OF DOT1L INHIBITOR PINOMETOSTAT
    Publication number: 20200009176
    Abstract: The present invention relates to DOT1L inhibitors.
    Type: Application
    Filed: May 17, 2019
    Publication date: January 9, 2020
    Inventors: Roy M. POLLOCK, Scott R. DAIGLE, Eric HEDRICK, Nigel WATERS, Blythe THOMSON
  • TREATMENT OF LEUKEMIA VIA THE ADMINISTRATION OF DOT1L INHIBITOR PINOMETOSTAT
    Publication number: 20190076455
    Abstract: The present invention relates to a method for the treatment of leukemia and the induction of leukemic blast cell maturation or differentiation via the administration of the DOT1L inhibitor pinometostat (otherwise known as EPZ-5676; CAS Registry number 1380288-87-8) or its N-oxide or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 4, 2015
    Publication date: March 14, 2019
    Inventors: Roy M. POLLOCK, Scott R. DAIGLE, Eric HEDRICK, Nigel WATERS, Blythe THOMSON
  • PEDIATRIC DOSING FOR TREATMENT OF CANCER WITH AN EZH2 INHIBITOR
    Publication number: 20190070188
    Abstract: The disclosure provides a method of treating a an INI1-deficient tumor in a subject in need thereof comprising administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In a preferred embodiment of this method, the subject is pediatric and the EZH2 inhibitor is Tazemetostat.
    Type: Application
    Filed: November 7, 2016
    Publication date: March 7, 2019
    Inventors: Heike KEILHACK, Sarah K. KNUTSON, Nigel WATERS
  • Methods for treating cancer
    Patent number: 10143704
    Abstract: The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: December 4, 2018
    Assignee: Epizyme, Inc.
    Inventors: Roy M. Pollock, Scott R. Daigle, Eric Hedrick, Nigel Waters, Blythe Thomson
  • METHODS FOR TREATING CANCER
    Publication number: 20160296548
    Abstract: The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: November 13, 2014
    Publication date: October 13, 2016
    Inventors: Roy M. Pollock, Scott R. Daigle, Eric Hedrick, Nigel Waters, Blythe Thomson